Maki Arakawa-Todo   Takahiko Yoshizawa   Kenji Zennami   Genya Nishikawa   Yoshiharu Kato   Ikuo Kobayashi   Keishi Kajikawa   Yoshiaki Yamada   Katsuhiko Matsuura   Ikuto Tsukiyama   Hiroko Saito   Takaaki Hasegawa   Kogenta Nakamura   Makoto Sumitomo   
Anticancer research 33(11) 5043-50 2013年11月
Patients with progressive renal cell carcinoma who undergo sunitinib treatment, experience many adverse events (AEs), including thrombopenia and hypertension. Dose reduction or treatment discontinuation due to AEs makes it difficult to control the...